Vestal Point Capital, LP
Long book
$3.58B
Q1 2026
Positions
90
Top-10 weight
40%
concentration
Last quarter
+24.1%
SPY +14.8%
Turnover
53%
of book per quarter
Strategy in plain words
auto-generated from filingsVestal Point Capital, LP is a diversified fundamental manager, specialised in healthcare (99% of the long book), running a $3.58B US long book across 90 positions.
The portfolio is moderately concentrated (top 10 ≈ 40% of the book). Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: REVOLUTION MEDICINES INC, BIOMARIN PHARMACEUTICAL INC, ABIVAX SA-ADR, NEUROCRINE BIOSCIENCES INC, ARROWHEAD PHARMACEUTICALS IN.
Over the last 9 quarters its long book ran on average 4.4pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-2.3%
Q2 2024
+8.6%
Q3 2024
-4.1%
Q4 2024
-13.1%
Q1 2025
+1.8%
Q2 2025
+37.8%
Q3 2025
+26.0%
Q4 2025
+0.8%
Q1 2026
+24.1%
Sector allocation
Healthcare 95%
Other 4%
Materials 1%
Long book by quarter
What does Vestal Point own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| RVMD REVOLUTION MEDICINES INC | Healthcare | 2.4M | $231.0M | 6.5% | +705.1% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.6M | $202.0M | 5.6% | +19.2% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.3M | $164.7M | 4.6% | New |
| ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 2.3M | $142.6M | 4.0% | +152.8% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.3M | $127.4M | 3.6% | -15.1% |
| RGEN REPLIGEN CORP | Healthcare | 925.0K | $109.0M | 3.0% | +1014.5% |
| BCAX BICARA THERAPEUTICS INC | Healthcare | 5.4M | $107.9M | 3.0% | +51.7% |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 6.5M | $100.8M | 2.8% | +38.6% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 1.1M | $92.6M | 2.6% | +100.0% |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 18.0M | $80.5M | 2.2% | +30.9% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 4.0M | $72.5M | 2.0% | +3233.3% |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 7.0M | $66.9M | 1.9% | +212.2% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 1.3M | $65.1M | 1.8% | +89.2% |
| IMTX IMMATICS NV | Healthcare | 6.2M | $60.8M | 1.7% | +0.8% |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 1.0M | $60.6M | 1.7% | +300.0% |
| ALC ALCON INC | Healthcare | 800.0K | $60.3M | 1.7% | -27.6% |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 3.6M | $59.3M | 1.7% | +365.0% |
| VERA VERA THERAPEUTICS INC | Healthcare | 1.4M | $55.0M | 1.5% | +148.8% |
| 430 TERNS PHARMACEUTICALS INC | — | 1.0M | $52.7M | 1.5% | -77.8% |
| GMED GLOBUS MEDICAL INC - A | Healthcare | 610.5K | $52.6M | 1.5% | -52.1% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 800.0K | $50.2M | 1.4% | New |
| NUVL NUVALENT INC-A | Healthcare | 481.7K | $49.4M | 1.4% | +947.2% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 1.2M | $47.4M | 1.3% | New |
| ANRO ALTO NEUROSCIENCE INC | Healthcare | 2.1M | $46.4M | 1.3% | -16.9% |
| RAPP RAPPORT THERAPEUTICS INC | Healthcare | 1.4M | $44.9M | 1.3% | +29.4% |
| IRON DISC MEDICINE INC | Healthcare | 700.0K | $44.8M | 1.3% | -4.8% |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 75.0K | $44.5M | 1.2% | New |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 1.2M | $38.8M | 1.1% | +5.1% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 1.9M | $37.2M | 1.0% | -2.1% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 639.9K | $37.2M | 1.0% | +6.7% |
| SLDB SOLID BIOSCIENCES INC | Healthcare | 5.0M | $36.0M | 1.0% | -14.0% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 492.3K | $35.9M | 1.0% | New |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 326.2K | $34.4M | 1.0% | New |
| DNLI DENALI THERAPEUTICS INC | Healthcare | 1.8M | $34.0M | 1.0% | +281.4% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 40.0K | $30.9M | 0.9% | New |
| WAT WATERS CORP | Healthcare | 100.0K | $29.8M | 0.8% | New |
| VKTX VIKING THERAPEUTICS INC | Healthcare | 914.1K | $29.7M | 0.8% | New |
| INSP INSPIRE MEDICAL SYSTEMS INC | Healthcare | 539.3K | $27.8M | 0.8% | New |
| CBIO CRESCENT BIOPHARMA INC | Healthcare | 1.5M | $27.6M | 0.8% | Held |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.2M | $25.8M | 0.7% | New |
| LXEO LEXEO THERAPEUTICS INC | Healthcare | 4.5M | $25.7M | 0.7% | Held |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 730.0K | $24.4M | 0.7% | New |
| BBNX BETA BIONICS INC | Healthcare | 2.2M | $22.2M | 0.6% | +268.6% |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 285.0K | $20.5M | 0.6% | New |
| CYTK CYTOKINETICS INC | Healthcare | 300.0K | $19.8M | 0.6% | New |
| AZN ASTRAZENECA PLC | Healthcare | 100.0K | $19.7M | 0.6% | New |
| WST WEST PHARMACEUTICAL SERVICES | Healthcare | 75.0K | $18.8M | 0.5% | New |
| GEHC GE HEALTHCARE TECHNOLOGY | Healthcare | 250.0K | $17.8M | 0.5% | New |
| SGP SPYGLASS PHARMA INC | Healthcare | 666.8K | $17.3M | 0.5% | New |
| ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 190.0K | $17.2M | 0.5% | +26.7% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 90 | $3.58B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 76 | $2.94B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 81 | $2.21B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 72 | $1.90B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 63 | $1.40B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 73 | $1.69B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 69 | $1.32B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 60 | $1.34B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 58 | $1.21B | canonical | SEC ↗ |